세계의 겸상 적혈구증 치료 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 치료별, 최종 용도별, 지역별, 경쟁별(2020-2030년)

Global Sickle Cell Disease Treatment market was valued at USD 1.22 billion in 2024 and is expected to reach USD 3.12 billion by 2030, growing at a CAGR of 16.91% during the forecast period. Sickle Cell Disease (SCD) is a genetic disorder characterized by the presence of abnormal hemoglobin, resulting in the deformation of red blood cells into a crescent or "sickle" shape. This altered cell structure leads to various complications, such as chronic pain, anemia, organ damage, and a shortened lifespan. The Sickle Cell Disease Treatment Market has undergone significant evolution over the years, with researchers and pharmaceutical companies striving to develop effective therapies that improve the quality of life for individuals affected by this condition. In the past, treatments for Sickle Cell Disease were primarily focused on symptom management and relieving pain. However, recent years have witnessed remarkable progress in the development of targeted therapies aimed at addressing the underlying genetic and physiological factors contributing to the disease.

Key Market Drivers

Increased Awareness and Advocacy

Increased awareness and advocacy have played a transformative role in how Sickle Cell Disease (SCD) is understood and managed worldwide. The efforts of patient advocacy groups, healthcare professionals, researchers, and families have brought much-needed attention to the burden faced by individuals living with SCD. As a result, global health agencies are recognizing SCD as a major public health issue. According to a 2024 report by the WHO, over 300,000 babies are born annually with SCD worldwide, with the majority in low- and middle-income countries highlighting the urgency for awareness and intervention. This growing visibility has translated into stronger public and political will to address the disease with improved care strategies.

People living with SCD and their families have become powerful voices in influencing policy and research agendas. Their real-life stories and advocacy have fostered a more compassionate approach to care and inspired systemic changes. Educational outreach initiatives have surged, particularly in high-prevalence regions. In 2023, the U.S. Centers for Disease Control and Prevention (CDC) reported a 25% increase in participation in community-based awareness programs on hemoglobinopathies, including SCD. This momentum has spurred early diagnosis programs, expanded screening services, and greater public engagement in supporting clinical trials for new treatments.

Pharmaceutical companies and research institutions are increasingly prioritizing SCD in their R&D pipelines, motivated by advocacy-driven funding and regulatory support. Gene therapy, one of the most promising avenues, is gaining attention as clinical trials reach late stages. Heightened awareness has also catalyzed collaborations between governments, biotech firms, and non-profits to address both treatment and accessibility gaps. These partnerships are contributing to a more equitable healthcare landscape for SCD patients, especially in underserved populations, and reflect the growing influence of organized advocacy in reshaping treatment strategies.

Public awareness campaigns have not only elevated understanding of the disease but also emphasized the importance of early and sustained medical intervention. Global health days dedicated to SCD, such as World Sickle Cell Day, are now recognized in over 50 countries, driving media attention and policy discussions. Meanwhile, policy-driven advocacy has led to the implementation of national SCD strategies in several countries, including India, Nigeria, and the U.K. As these collective efforts gain ground, they are setting a foundation for continued innovation, improved patient outcomes, and a future where living with SCD no longer equates to limited options and compromised quality of life.

Key Market Challenges

Access to Treatment

One of the most pressing challenges in the Sickle Cell Disease (SCD) treatment market is limited access to advanced therapies, particularly in low- and middle-income countries where the disease burden is highest. Despite the development of novel drugs and promising gene therapies, the majority of patients especially those in Sub-Saharan Africa and parts of South Asia lack access to these life-saving treatments due to inadequate healthcare infrastructure, high treatment costs, and insufficient availability of specialized care. Many healthcare systems in these regions face resource constraints, making it difficult to offer routine screening, diagnosis, and ongoing management. This disparity results in delayed or no treatment, contributing to increased morbidity, early mortality, and a reduced quality of life for many patients.

Additionally, even in high-income countries, socioeconomic and racial disparities pose significant barriers to accessing care. Patients from marginalized communities often struggle with affordability, insurance limitations, and geographic barriers to specialized treatment centers. Advanced therapies such as gene editing or biologics can cost hundreds of thousands of dollars per treatment, making them financially inaccessible for many, despite their potential to significantly improve outcomes. Moreover, a lack of awareness, provider biases, and limited clinical trial participation among underrepresented populations further widen the gap in care delivery. Addressing these access issues is critical to ensuring that breakthroughs in SCD treatment translate into real-world benefits for all patients, regardless of location or economic status.

Key Market Trends

Technological Advancements

One of the most revolutionary advancements in Sickle Cell Disease treatment is the development of gene editing technologies such as CRISPR-Cas9. This breakthrough allows scientists to precisely modify genetic material, offering the potential to correct the genetic mutations responsible for Sickle Cell Disease. With ongoing research and clinical trials, gene editing holds promise for a permanent cure, eliminating the root cause of the disease. This approach has the potential to transform Sickle Cell Disease treatment from symptom management to complete eradication. Stem cell therapies are also on the forefront of Sickle Cell Disease treatment innovation. Hematopoietic stem cell transplantation (HSCT) has shown significant potential in curing Sickle Cell Disease by replacing the patient's defective bone marrow with healthy stem cells. Technological advancements have enhanced the success rate and safety of HSCT procedures, expanding the pool of eligible patients and improving overall outcomes. Moreover, induced pluripotent stem cells (iPSCs) are being explored for their potential to generate healthy red blood cells for transfusion, reducing the need for frequent blood transfusions among Sickle Cell Disease patients.

Advances in data analytics and precision medicine are transforming the way healthcare professionals approach Sickle Cell Disease treatment. By analyzing vast amounts of patient data, including genetic information, medical histories, and treatment responses, researchers can identify patterns and tailor treatments to individual patients. This personalized approach increases the likelihood of successful outcomes and reduces adverse effects, ensuring that patients receive the most suitable and effective interventions. The rise of telemedicine has revolutionized patient care, enabling remote consultations, monitoring, and treatment management. This is especially valuable for individuals with Sickle Cell Disease, as it reduces the need for frequent hospital visits and allows patients to access expert care from the comfort of their homes. Remote monitoring devices can track vital signs, medication adherence, and disease progression, providing real-time data to healthcare providers and facilitating timely interventions.

Key Market Players

• Novartis AG
• Pfizer Inc.
• Bluebird Bio, Inc
  • GlycoMimetics
• Emmaus Medical, Inc
• Bristol-Myers Squibb Company
• CRISPR Therapeutics
• Graphite Bio, Inc.

Report Scope:

In this report, the Global Sickle Cell Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Sickle Cell Disease Treatment Market, By Treatment:

• Blood Transfusion
• Pharmacotherapy
• Bone Marrow Transplant

Sickle Cell Disease Treatment Market, By End-Use:

• Hospitals
• Specialty Clinics
• Others

Sickle Cell Disease Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Sickle Cell Disease Treatment Market.

Available Customizations:

Global Sickle Cell Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Sickle Cell Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant)
  • 5.2.2. By End-Use (Hospitals, Specialty Clinics. Others)
  • 5.2.3. By Company (2024)
  • 5.2.4. By Region
• 5.3. Market Map

6. North America Sickle Cell Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By End-Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Sickle Cell Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By End-Use
  • 6.3.2. Mexico Sickle Cell Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By End-Use
  • 6.3.3. Canada Sickle Cell Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By End-Use

7. Europe Sickle Cell Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By End-Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Sickle Cell Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By End-Use
  • 7.3.2. Germany Sickle Cell Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By End-Use
  • 7.3.3. United Kingdom Sickle Cell Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By End-Use
  • 7.3.4. Italy Sickle Cell Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By End-Use
  • 7.3.5. Spain Sickle Cell Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By End-Use

8. Asia-Pacific Sickle Cell Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By End-Use
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Sickle Cell Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By End-Use
  • 8.3.2. India Sickle Cell Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By End-Use
  • 8.3.3. South Korea Sickle Cell Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By End-Use
  • 8.3.4. Japan Sickle Cell Disease Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By End-Use
  • 8.3.5. Australia Sickle Cell Disease Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By End-Use

9. South America Sickle Cell Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By End-Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Sickle Cell Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By End-Use
  • 9.3.2. Argentina Sickle Cell Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By End-Use
  • 9.3.3. Colombia Sickle Cell Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By End-Use

10. Middle East and Africa Sickle Cell Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By End-Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Sickle Cell Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By End-Use
  • 10.3.2. Saudi Arabia Sickle Cell Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By End-Use
  • 10.3.3. UAE Sickle Cell Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Bluebird Bio, Inc
• 15.4. GlycoMimetics
• 15.5. Emmaus Medical, Inc
• 15.6. Bristol-Myers Squibb Company
• 15.7. CRISPR Therapeutics
• 15.8. Graphite Bio, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer